Vericiguat for Heart Failure With Leaky Tricuspid Valve and Right Heart Weakness
Tests vericiguat in adults with weak heart pumping and a leaky tricuspid valve.
Key facts
- Who runs it
- Daejeon St. Mary's hospital
- Where
- Daejeon, South KoreaSee the site
- Trial code
- Registry title
- Efficacy of Verciguat in TR and RV Failure
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 May 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Vericiguat
- Record updated
- 25 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure, weak left heart pumping and a leaky tricuspid valve, who also have right heart weakness.
- Age
- More than 19 years old
- Sex
- All sexes can join.
- Disease stage
- Chronic heart failure with LVEF<45%; right ventricle malfunction confirmed with EKG data or cardiac MRI; tricuspid regurgitation greater than moderate severity confirmed by echocardiogram. NTproBNP >1000, or >1600 with atrial fibrillation, or recent worsening heart failure (recent hospitalization or intravenous diuretics as an outpatient).
- Earlier treatment
- Must have had standard heart failure treatment for over 4 weeks. Must not have taken vericiguat in the last 6 months.
- Biomarker or test result
- NTproBNP >1000 (>1600 with atrial fibrillation), unless the person recently had worsening heart failure.
Main reasons for not taking part
- Systolic blood pressure (SBP) < 100 mmHg
- Currently treated with other sGC stimulators (including vericiguat) or PDE5 inhibitors
- Moderate-to-severe right ventricular failure needing surgery
- Currently pregnant or able to have children
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age more than 19 years old
- right ventricular malfunction confirmed with EKG data or cardiac MRI
- chronic heart failure with LVEF<45%
- Patients Who administrated standard treatment of Heart Failur for over the 4 weeks
- NTproBNP >1000, NTproBNP >1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics)
- Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram
- Subject who provided voluntary informed consent to participate in the study
- Patients who have not been administered vericiguat within the last 6 months
Who cannot take part
- Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors
- Moderate-to-severe right ventricular (RV) failure requiring surgical intervention
- Patients with a systolic blood pressure (SBP) < 100 mmHg
- Patients who are currently pregnant or of childbearing potential
Where in South Korea
- Daejeon St.Mary's HospitalDaejeon, South KoreaContact: Principle InvestigatorNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the drug vericiguat works to improve right heart function in patients with worsening heart failure who have reduced left ventricular function. It will also examine the effects of the drug on tricuspid regurgitation (TR) and overall clinical outcomes.
Read full original descriptionShow less
The main questions it aims to answer are:
Does vericiguat improve right ventricular (RV) function and reduce tricuspid regurgitation (TR)? Does vericiguat reduce the risk of major adverse cardiovascular events (MACE), such as heart failure hospitalizations and cardiovascular death? Does vericiguat improve participants' exercise capacity, quality of life, and renal function?
Researchers have previously seen the benefits of vericiguat in the large-scale VICTORIA trial for worsening heart failure, and it is hypothesized that improvements in right heart function play a key role. This study aims to confirm these specific benefits.
Participants will:
Take vericiguat as prescribed during the study period. Undergo echocardiograms at enrollment and at 9 months to assess right heart function.
Complete questionnaires (KCCQ-12) and walking tests (6MWT) to evaluate quality of life and exercise capacity.
Provide blood samples to monitor NTproBNP levels and renal function (creatinine).
The 2 groups in the trial
- Arm with administered with VericiguatTreatment being tested
Subjects assigned to the experimental arm will initiate vericiguat at a daily dose of 2.5 mg, concurrently with their baseline heart failure therapy including standard of care (loop diuretics, MRAs, and SGLT2i). The dose will be targeted to double every 2 weeks, titrating up to a maximum dose of 10 mg.
Treatment: Vericiguat
- Arm with standard of careNo study treatment, for comparison
This arm is classified as the standard of care control group, where participants receive baseline heart failure therapies including loop diuretics, MRAs, and SGLT2i. During the study period, if a participant in this arm exhibits no symptomatic improvement or demonstrates clinical worsening despite baseline therapy, the investigator will re-evaluate the doses of the existing standard medications and titrate them up to the maximum recommended doses within a permissible range, or adjust the medication combination to prioritize patient safety. Additionally, in cases of accompanied fluid overload, further pharmacological interventions, including the adjustment of diuretics, may be administered.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial
- Plain-language title
- Vericiguat for Heart Failure With Leaky Tricuspid Valve and Right Heart WeaknessGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 June 2026